Consumer views on the use of digital tools for reporting adverse drug reactions: a cross-sectional study
Open Access
- 19 December 2024
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 47 (2) , 423-434
Abstract
Background: The application of digital technologies has shown benefits in enhancing pharmacovigilance activities but consumers views on the use of these tools for this purpose are not well described. Aim: To explore consumers’ views on using digital tools to report adverse drug reactions (ADRs) and identify key features that consumers want in digital tools for ADR reporting. Method: An online survey was conducted among adults who had taken medicine in the previous six-months in Australia. The development of questions was guided by the Combined Technology Acceptance Model and Theory of Planned Behaviour (C-TAM-TPB) framework. Responses to closed-ended questions were analysed using descriptive statistics and chi-square/Fisher’s exact test, while free-text responses were analysed using qualitative content analysis. Results: A total of 494 responses were included in the analysis. Eighty-seven percent of respondents preferred using digital tools for reporting ADRs. Consumers indicated a free-text space for describing ADRs (90%) as important or very important features of digital tools for ADR reporting, followed by acknowledgement of their report submission (87%) and receiving summary of previously reported ADRs (87%). Women (p < 0.001), advanced smartphone users (p < 0.001), and previous digital healthcare tool users (p = 0.017) showed higher intention to use digital tools. Consumers emphasized the importance of ease-of-use, accessibility, receiving medicine safety information, feedback, and advice for reporting ADRs via digital tools. Conclusion: Consumers prefer using digital tools for reporting ADRs and place high value on features such as a free-text space for describing ADRs, acknowledgement of report submissions, and access to summaries of previously submitted reports.Keywords
Funding Information
- University of South Australia
- National Health and Medical Research Council (APP2020626)
This publication has 42 references indexed in Scilit:
- Consumers’ knowledge and experiences of adverse drug reaction reporting in Australia: a national surveyEuropean Journal of Clinical Pharmacology, 2024
- Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains frameworkInternational Journal of Clinical Pharmacy, 2023
- Factors associated with underreporting of adverse drug reactions by patients: a systematic reviewInternational Journal of Clinical Pharmacy, 2023
- Evolution of adverse drug reactions reporting systems: paper based to software basedEuropean Journal of Clinical Pharmacology, 2022
- A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issuesEuropean Journal of Clinical Pharmacology, 2021
- Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative reviewInternational Journal of Clinical Pharmacy, 2020
- Current trends in pharmacovigilance: value and gaps of patient reportingInternational Journal of Clinical Pharmacy, 2018
- The Use of Cronbach’s Alpha When Developing and Reporting Research Instruments in Science EducationResearch in Science Education, 2017
- Pharmacovigilance: empowering healthcare professionals and patientsInternational Journal of Clinical Pharmacy, 2014
- Motives for reporting adverse drug reactions by patient-reporters in the NetherlandsEuropean Journal of Clinical Pharmacology, 2010